These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 17331885)

  • 1. Emerging host cell targets for hepatitis C therapy.
    He Y; Duan W; Tan SL
    Drug Discov Today; 2007 Mar; 12(5-6):209-17. PubMed ID: 17331885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The hepatitis C virus life cycle as a target for new antiviral therapies.
    Pawlotsky JM; Chevaliez S; McHutchison JG
    Gastroenterology; 2007 May; 132(5):1979-98. PubMed ID: 17484890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies.
    Zeisel MB; Fofana I; Fafi-Kremer S; Baumert TF
    J Hepatol; 2011 Mar; 54(3):566-76. PubMed ID: 21146244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A primer on the molecular virology of hepatitis C.
    Moradpour D; Blum HE
    Liver Int; 2004 Dec; 24(6):519-25. PubMed ID: 15566499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of chronic hepatitis C virus infection - Dutch national guidelines.
    de Bruijne J; Buster EH; Gelderblom HC; Brouwer JT; de Knegt RJ; van Erpecum KJ; Schalm SW; Bakker CM; Zaaijer HL; Janssen HL; Reesink HW;
    Neth J Med; 2008; 66(7):311-22. PubMed ID: 18663263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C therapeutics: current status and emerging strategies.
    Tan SL; Pause A; Shi Y; Sonenberg N
    Nat Rev Drug Discov; 2002 Nov; 1(11):867-81. PubMed ID: 12415247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune responses in hepatitis C virus infection and mechanisms of hepatitis C virus persistence.
    Hiroishi K; Ito T; Imawari M
    J Gastroenterol Hepatol; 2008 Oct; 23(10):1473-82. PubMed ID: 18761560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation systems for anti-HCV drugs.
    Moriishi K; Matsuura Y
    Adv Drug Deliv Rev; 2007 Oct; 59(12):1213-21. PubMed ID: 17720275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New therapies for hepatitis C virus infection.
    Soriano V; Peters MG; Zeuzem S
    Clin Infect Dis; 2009 Feb; 48(3):313-20. PubMed ID: 19123867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults.
    Rockstroh JK; Bhagani S; Benhamou Y; Bruno R; Mauss S; Peters L; Puoti M; Soriano V; Tural C;
    HIV Med; 2008 Feb; 9(2):82-8. PubMed ID: 18257771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus genetic variability in patients undergoing antiviral therapy.
    Cristina J; del Pilar Moreno M; Moratorio G
    Virus Res; 2007 Aug; 127(2):185-94. PubMed ID: 17449128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening of small-molecule compounds as inhibitors of HCV entry.
    Yang JP; Zhou D; Wong-Staal F
    Methods Mol Biol; 2009; 510():295-304. PubMed ID: 19009270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of intracellular hepatitis C virus replication by nelfinavir and synergistic effect with interferon-alpha.
    Toma S; Yamashiro T; Arakaki S; Shiroma J; Maeshiro T; Hibiya K; Sakamoto N; Kinjo F; Tateyama M; Fujita J
    J Viral Hepat; 2009 Jul; 16(7):506-12. PubMed ID: 19302339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How does interferon inhibit HCV cell entry?
    Jones M; Owen JS
    Gut; 2008 May; 57(5):573-4. PubMed ID: 18408099
    [No Abstract]   [Full Text] [Related]  

  • 15. Cellular and molecular biology of HCV infection and hepatitis.
    Tang H; Grisé H
    Clin Sci (Lond); 2009 Jun; 117(2):49-65. PubMed ID: 19515018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C virus virology and new treatment targets.
    Meier V; Ramadori G
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):329-50. PubMed ID: 19344246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-density lipoprotein receptor variants are associated with spontaneous and treatment-induced recovery from hepatitis C virus infection.
    Mas Marques A; Mueller T; Welke J; Taube S; Sarrazin C; Wiese M; Halangk J; Witt H; Ahlenstiel G; Spengler U; Goebel U; Schott E; Weich V; Schlosser B; Wasmuth HE; Lammert F; Berg T; Schreier E
    Infect Genet Evol; 2009 Sep; 9(5):847-52. PubMed ID: 19446659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histamine dihydrochloride: actions and efficacy in the treatment of chronic hepatitis C infection.
    Lalazar G; Ilan Y
    Expert Rev Anti Infect Ther; 2006 Jun; 4(3):377-85. PubMed ID: 16771615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-retroviral drugs do not facilitate hepatitis C virus (HCV) infection in vitro.
    Sandmann L; Wilson M; Back D; Wedemeyer H; Manns MP; Steinmann E; Pietschmann T; von Hahn T; Ciesek S
    Antiviral Res; 2012 Oct; 96(1):51-8. PubMed ID: 22842003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Host factors involved in the replication of hepatitis C virus.
    Moriishi K; Matsuura Y
    Rev Med Virol; 2007; 17(5):343-54. PubMed ID: 17563922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.